00000000cam 2200000zi 4500
0019.965736
003CaOODSP
00520261008094231
006m     o  d f      
007cr mn|||||||||
008260909t20262026onca    os   f000 0 eng d
020 |a9781100004822
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aHP40-408/3-2026E-PDF
24500|aTracks survey findings 2023-2025 : |boverdose, Naloxone & community care : key insights from people who inject drugs.
24610|aOverdose, Naloxone and community care :|bkey insights from people who inject drugs
264 1|a[Ottawa] : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c[2026]
264 4|c©2026
300 |a1 online resource (1 page) : |billustrations
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Résultats de l’enquête Track 2023-2025 : surdose, naloxone & soins communautaires : principaux résultats chez les personnes qui utilisent des drogues par injection.
500 |aCaption title.
650 0|aIntravenous drug abusers|zCanada|xAttitudes|vStatistics.
650 0|aIntravenous drug abusers|xHealth risk assessment|zCanada|vStatistics.
650 0|aDrugs|xOverdose|zCanada|vStatistics.
655 7|aStatistics|2lcgft
655 7|aInfographics|2lcgft
7102 |aPublic Health Agency of Canada, |eissuing body.
77508|tRésultats de l’enquête Track 2023-2025 : |w(CaOODSP)9.965735
85640|qPDF|s180 KB|uhttps://publications.gc.ca/collections/collection_2026/aspc-phac/HP40-408-3-2026-eng.pdf
8564 |qHTML|sN/A|uhttps://training-formation.phac-aspc.gc.ca/course/section.php?id=4811
986 |a260301